Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

Ugurlu S., Hacioglu A., Adibnia Y., HAMURYUDAN V., Ozdogan H.

ORPHANET JOURNAL OF RARE DISEASES, vol.12, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2017
  • Doi Number: 10.1186/s13023-017-0642-0
  • Journal Name: ORPHANET JOURNAL OF RARE DISEASES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Keywords: Familial Mediterranian fever, Tocilizumab, AA amyloidosis, ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, NEPHROTIC SYNDROME, DISEASE, ARTHRITIS, MULTICENTER, REMISSION, EFFICACY, CRITERIA, THERAPY, PROTEIN
  • Erciyes University Affiliated: No

Abstract

Background: There is no established treatment of AA amyloidosis, a long-term complication of various chronic inflammatory diseases associated with increased mortality, such as familial Mediterranian fever (FMF). Recently there are few reports pointing out that tocilizumab(TCZ), an anti IL-6 agent may be effective in AA amyloidosis resistant to conventional treatments. We report our data on the effect of TCZ in patients with FMF complicated with AA amyloidosis.